Breast Cancer Brain Metastases and ERBB2 / HER2 Activating Mutations https://t.co/y59iv3sNSb https://t.co/wd0eRfab5H
RT @npriedig: Our work on HER2/other gains in breast cancer brain mets out in @JAMAOnc @Adrianvlee @oesterreichs @AhmedBasudan1 @wattersrj…
RT @npriedig: Our work on HER2/other gains in breast cancer brain mets out in @JAMAOnc @Adrianvlee @oesterreichs @AhmedBasudan1 @wattersrj…
RT @amir_bahreini: It is time to consider Her2 evaluation in metastatic breast cancer @npriedig #practice_changing_research https://t.co/0y…
RT @npriedig: Our work on HER2/other gains in breast cancer brain mets out in @JAMAOnc @Adrianvlee @oesterreichs @AhmedBasudan1 @wattersrj…
RT @npriedig: Our work on HER2/other gains in breast cancer brain mets out in @JAMAOnc @Adrianvlee @oesterreichs @AhmedBasudan1 @wattersrj…
Our work on HER2/other gains in breast cancer brain mets out in @JAMAOnc @Adrianvlee @oesterreichs @AhmedBasudan1 @wattersrj #sabcs #sabcs16 https://t.co/BrrqKWsjWH
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @JAMAOnc: Molec profiling of brain mets in #BreastCancer often IDs clinically relevant results diff from primary #tumor https://t.co/eUb…
Molec profiling of brain mets in #BreastCancer often IDs clinically relevant results diff from primary #tumor https://t.co/eUbbJDA0I5 #BCSM
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
RT @amir_bahreini: It is time to consider Her2 evaluation in metastatic breast cancer @npriedig #practice_changing_research https://t.co/0y…
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
It is time to consider Her2 evaluation in metastatic breast cancer @npriedig #practice_changing_research https://t.co/0y0ICbeKuc
Great paper from @npriedig Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amps and Mutations in Breast Cancer Brain Mets. #sabcs16 https://t.co/8uHqdoEnff
20% of HER2 negative BC gain HER2 expression in brain metastasis https://t.co/wWHecU6rdB
RT @JAMAOnc: Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Z…
Brain mets in #BreastCancer frequently develop clinically relevant, suggesting value to molecular profiling https://t.co/Umr1Zy2Mrr #BCSM